



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

12th February 2025
IOLCP/CGC/2025

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051

Security Symbol: IOLCP

BSE Limited,

Pheroze Jeejeebhoy Tower,
Dalal Street, Mumbai- 400 001

Security Code: 524164

Subject: Outcome of the Board Meeting and submission of Un-Audited Financial Results for the quarter and nine months ended 31st December 2024

Dear Sir,

Pursuant to Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at their meeting held on today i.e. 12th February 2024 has inter alia considered and approved:

1. The Standalone & Consolidated Un-Audited Financial Results for the quarter and nine months ended 31st December 2024. Copy of the said Financial Results alongwith Limited Review Report of Statutory Auditors is enclosed herewith as "**Annexure – 1**".
2. Declared an Interim Dividend of Rs. 4/- (40%) per Equity Share of Face Value Rs.10/-* each for the Financial Year 2024-25 and fixed 18th February 2025 as the Record Date to determine the names of the equity shareholders, who shall be entitled to receive the above said Interim Dividend.

**[The Interim Dividend of Rs 4/- per share has been considered on equity share of Face Value of Rs. 10 each, as the sub-division / split of share of face value of Rs. 10/- each into 5 equity shares of Face Value of Rs. 2/- each (which was approved by the shareholders vide postal ballot on 31st January 2025) is in the process and will be implemented based on the Record Date fixed for 11th March 2025].*

The payment of the Interim Dividend shall be made to the eligible shareholders within 30 days of declaration.

The meeting of the Board of Directors commenced at 4:15 PM and concluded at 5:40 PM.

The above Un-Audited Financial Results along with Limited Review Report of Statutory Auditors are also available on the website of the Company i.e. www.iolcp.com.

This is for your information & record.

Thanking You,
Yours faithfully,
for **IOL Chemicals and Pharmaceuticals Limited**

Abhay Raj Singh
Sr. Vice President & Company Secretary

Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
IOL Chemicals & Pharmaceuticals Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **M/s IOL Chemicals & Pharmaceuticals Limited** (the "Company") for the quarter and nine months period ended 31st December ,2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data. A review is substantially less in scope than an audit conducted in accordance with Standard on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other



accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ashwani & Associates

Chartered Accountants

Firm Registration No.: 000497N

by the hand of



Arvind Jain

Partner

M. No.: 097549

UDIN: 25097549BMGRHX1072

Place: Ludhiana

Dated: 12.02.2025



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS PERIOD ENDED 31-DECEMBER-2024

in ₹ Crore

Sr. No.	Particulars	Quarter ended			Nine months period ended		Year ended
		31-Dec-2024 (Unaudited)	30-Sep-2024 (Unaudited)	31-Dec-2023 (Audited)	31-Dec-2024 (Unaudited)	31-Dec-2023 (Audited)	31-Mar-2024 (Audited)
	Income:						
I	Revenue from operations	523.30	525.75	520.39	1,551.43	1,628.87	2,132.79
II	Other Income	4.07	6.43	8.38	17.88	22.55	30.07
III	Total income (I+II)	527.37	532.18	528.77	1,569.31	1,651.42	2,162.86
	Expenses:						
IV	Cost of materials consumed	335.96	351.75	358.06	1,010.73	1,085.75	1,435.05
	Purchases of stock-in-trade	-	-	-	-	0.15	0.15
	Changes in inventories of finished goods, work-in-progress and stock in trade	18.09	3.89	(2.11)	35.33	(11.47)	(38.25)
	Employee benefits expense	52.43	58.70	48.29	164.18	151.37	201.02
	Finance costs	4.46	4.12	4.30	10.73	12.69	16.10
	Depreciation and amortization expenses	18.66	17.93	16.32	53.39	46.43	62.85
	Other expenses	69.95	69.85	71.67	201.96	221.63	303.30
	Total Expenses (IV)	499.55	506.24	496.53	1,476.32	1,506.55	1,980.22
V	Profit before exceptional items and tax (III-IV)	27.82	25.94	32.24	92.99	144.87	182.64
VI	Exceptional items	-	-	-	-	-	-
VII	Profit before tax (V-VI)	27.82	25.94	32.24	92.99	144.87	182.64
VIII	Tax Expense:						
	Current tax	4.34	4.57	6.28	17.68	31.99	37.01
	Deferred tax	2.93	2.22	2.73	5.93	5.65	10.21
	Total tax expense	7.27	6.79	9.01	23.61	37.64	47.22
IX	Profit for the period (VII-VIII)	20.55	19.15	23.23	69.38	107.23	135.42
X	Other Comprehensive Income						
A	Items that will not be reclassified to profit or loss						
(i)	Remeasurement gain/(loss) of defined benefit obligation	(0.06)	(0.04)	0.13	(1.91)	(2.12)	(1.71)
(ii)	Income tax relating to items that will not be reclassified to profit or loss	0.01	0.01	(0.03)	0.48	0.54	0.43
B	Items that will be reclassified to profit or loss						
(i)	Net movement in effective portion of cash flow hedge reserve	(0.09)	0.15	0.02	(0.04)	(0.02)	(0.01)
(ii)	Income tax relating to items that will be reclassified to profit or loss	0.03	(0.04)	(0.01)	0.01	-	-
XI	Total Comprehensive Income for the period (IX+X)	20.44	19.23	23.34	67.92	105.63	134.13
XII	Paid-up equity share capital (Face value ₹10/- per share)	58.71	58.71	58.71	58.71	58.71	58.71
XIII	Other equity (Reserves excluding revaluation reserve)	1,620.54	1,600.10	1,553.47	1,620.54	1,553.47	1,552.62
XIV	Earning per equity share of ₹10/- each (for continuing and discontinued operations) (not annualised except for the year ended 31-Mar-2024) Basic and Diluted ₹	3.50	3.26	3.96	11.82	18.27	23.07



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Punjab) India CIN - L24116PB1986PLC007030
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
 Regd. Office: Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India.
 Works: Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India.
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

STANDALONE SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES

in ₹ Crore

Sr.No.	Particulars	Quarter ended			Nine months period ended		Year ended
		31-Dec-2024	30-Sep-2024	31-Dec-2023	31-Dec-2024	31-Dec-2023	31-Mar-2024
		(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
1	Segment Revenue						
	(Net sale/income)						
	- Chemical	275.14	284.28	286.01	818.15	877.09	1,140.24
	- Pharmaceutical	300.58	293.81	287.01	890.05	967.39	1,262.54
	- Unallocated	4.07	6.43	9.33	17.88	26.96	35.87
	Total	579.79	584.52	582.35	1,726.08	1,871.44	2,438.65
	Less : Inter segment revenue	52.42	52.34	53.58	156.77	220.02	275.79
	Net sales/income from operations	527.37	532.18	528.77	1,569.31	1,651.42	2,162.86
2	Segment Results						
	Profit before tax and interest						
	(from each segment)						
	- Chemical	4.72	1.92	0.84	8.87	13.88	15.07
	- Pharmaceutical	26.14	24.60	34.57	85.35	135.05	174.22
	Total	30.86	26.52	35.41	94.22	148.93	189.29
	Less: Interest	4.46	4.12	4.30	10.73	12.69	16.10
	Add: Other un-allocable income net off un-allocable expenditure	1.42	3.54	1.13	9.50	8.63	9.45
	Total Profit before tax & Extraordinary items	27.82	25.94	32.24	92.99	144.87	182.64
3	Segment Assets						
	- Chemical	531.33	552.51	522.66	531.33	522.66	558.40
	- Pharmaceutical	1,317.03	1,293.21	1,207.19	1,317.03	1,207.19	1,254.54
	- Unallocated	457.11	418.89	449.24	457.11	449.24	431.03
	Total Assets	2,305.47	2,264.61	2,179.09	2,305.47	2,179.09	2,243.97
4	Segment Liabilities						
	- Chemical	219.44	207.57	237.25	219.44	237.25	330.66
	- Pharmaceutical	180.72	170.98	164.21	180.72	164.21	150.11
	- Unallocated	226.06	227.25	165.45	226.06	165.45	151.87
	Total Liabilities	626.22	605.80	566.91	626.22	566.91	632.64



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Punjab) India CIN - L24116PB1986PLC007030
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
 Regd. Office : Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India.
 Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India.
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292

Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
IOL Chemicals & Pharmaceuticals Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **M/s IOL Chemicals & Pharmaceuticals Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months period ended 31st December, 2024 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. The Statement includes the results of the Parent and the following entities:

Subsidiary Companies

- i. M/s IOL Speciality Chemicals Limited
- ii. M/s IOL Life Sciences Limited
- iii. M/s IOL Foundation


5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ashwani & Associates

Chartered Accountants

Firm Registration No.: 000497N

by the hand of



Arvind Jain

Partner

M. No.:097549

UDIN: 25097549BMGRHY6480

Place: Ludhiana

Dated:12.02.2025



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS PERIOD ENDED 31-DECEMBER-2024

in ₹ Crore

Sr. No.	Particulars	Quarter ended			Nine months period ended		Year ended
		31-Dec-2024	30-Sep-2024	31-Dec-2023	31-Dec-2024	31-Dec-2023	31-Mar-2024
		(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
	Income:						
I	Revenue from operations	523.30	525.75	520.39	1,551.43	1,628.87	2,132.79
II	Other Income	4.07	6.43	8.38	17.88	22.55	30.07
III	Total income (I+II)	527.37	532.18	528.77	1,569.31	1,651.42	2,162.86
	Expenses:						
IV	Cost of materials consumed	335.96	351.75	358.06	1,010.73	1,085.75	1,435.05
	Purchases of stock-in-trade	-	-	-	-	0.15	0.15
	Changes in inventories of finished goods, work-in-progress and stock in trade	18.09	3.89	(2.11)	35.33	(11.47)	(38.25)
	Employee benefits expense	52.43	58.70	48.29	164.18	151.37	201.02
	Finance costs	4.46	4.12	4.30	10.73	12.69	16.10
	Depreciation and amortization expenses	18.68	17.94	16.34	53.44	46.48	62.91
	Other expenses	69.95	69.84	71.80	201.64	222.00	304.23
	Total Expenses (IV)	499.57	506.24	496.68	1,476.05	1,506.97	1,981.21
V	Profit before exceptional items and tax (III-IV)	27.80	25.94	32.09	93.26	144.45	181.65
VI	Exceptional items	-	-	-	-	-	-
VII	Profit before tax (V-VI)	27.80	25.94	32.09	93.26	144.45	181.65
VIII	Tax Expense:						
	Current tax	4.34	4.57	6.28	17.68	31.99	37.01
	Deferred tax	2.93	2.22	2.73	5.93	5.65	10.21
	Total tax expense	7.27	6.79	9.01	23.61	37.64	47.22
IX	Profit for the period (VII-VIII)	20.53	19.15	23.08	69.65	106.81	134.43
X	Other Comprehensive Income						
A	Items that will not be reclassified to profit or loss						
(i)	Remeasurement gain/(loss) of defined benefit obligation	(0.06)	(0.04)	0.13	(1.91)	(2.12)	(1.71)
(ii)	Income tax relating to items that will not be reclassified to profit or loss	0.01	0.01	(0.03)	0.48	0.54	0.43
B	Items that will be reclassified to profit or loss						
(i)	Net movement in effective portion of cash flow hedge reserve	(0.09)	0.15	0.02	(0.04)	(0.02)	(0.01)
(ii)	Income tax relating to items that will be reclassified to profit or loss	0.03	(0.04)	(0.01)	0.01	-	-
XI	Total Comprehensive Income for the period (IX+X)	20.42	19.23	23.19	68.19	105.21	133.14
XII	Paid-up equity share capital (Face value ₹10/- per share)	58.71	58.71	58.71	58.71	58.71	58.71
XIII	Other equity (Reserves excluding revaluation reserve)	1,620.99	1,600.57	1,554.22	1,620.99	1,554.22	1,552.80
XIV	Earning per equity share of ₹10/- each (for continuing and discontinued operations) (not annualised except for the year ended 31-Mar-2024)						
	Basic and Diluted ₹	3.50	3.26	3.93	11.87	18.19	22.90



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Punjab) India CIN - L24116PB1986PLC007000
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
 Regd. Office: Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India.
 Works: Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India.
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

CONSOLIDATED SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES

in ₹ Crore

Sr.No.	Particulars	Quarter ended			Nine months period ended		Year ended
		31-Dec-2024 (Unaudited)	30-Sep-2024 (Unaudited)	31-Dec-2023 (Audited)	31-Dec-2024 (Unaudited)	31-Dec-2023 (Audited)	31-Mar-2024 (Audited)
1	Segment Revenue						
	(Net sale/income)						
	- Chemical	275.14	284.28	286.01	818.15	877.09	1,140.24
	- Pharmaceutical	300.58	293.81	287.01	890.05	967.39	1,262.54
	- Unallocated	4.07	6.43	9.33	17.88	26.96	35.87
	Total	579.79	584.52	582.35	1,726.08	1,871.44	2,438.65
	Less : Inter segment revenue	52.42	52.34	53.58	156.77	220.02	275.79
	Net sales/income from operations	527.37	532.18	528.77	1,569.31	1,651.42	2,162.86
2	Segment Results						
	Profit before tax and interest (from each segment)						
	- Chemical	4.72	1.92	0.84	8.87	13.88	15.07
	- Pharmaceutical	26.14	24.60	34.57	85.35	135.05	174.22
	Total	30.86	26.52	35.41	94.22	148.93	189.29
	Less: Interest	4.46	4.12	4.30	10.73	12.69	16.10
	Add: Other un-allocable income net off un-allocable expenditure	1.40	3.54	0.98	9.77	8.21	8.46
	Total Profit before tax & Extraordinary items	27.80	25.94	32.09	93.26	144.45	181.65
3	Segment Assets						
	- Chemical	531.33	552.51	522.66	531.33	522.66	558.40
	- Pharmaceutical	1,317.03	1,293.21	1,207.19	1,317.03	1,207.19	1,254.54
	- Unallocated	457.59	419.38	450.07	457.59	450.07	431.46
	Total Assets	2,305.95	2,265.10	2,179.92	2,305.95	2,179.92	2,244.40
4	Segment Liabilities						
	- Chemical	219.44	207.57	237.25	219.44	237.25	330.66
	- Pharmaceutical	180.72	170.98	164.21	180.72	164.21	150.11
	- Unallocated	226.09	227.27	165.53	226.09	165.53	152.12
	Total Liabilities	626.25	605.82	566.99	626.25	566.99	632.89



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Punjab) India CIN - L24116PB1986PLC007030
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
 Regd. Office : Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India.
 Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India.
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

NOTES:

1. The above standalone and consolidated un-audited financial results for the quarter and nine months ended 31st December 2024 have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their meetings held on 12th February 2025. These results have been subjected to limited review by Statutory Auditors who have expressed an unmodified opinion on these results.
2. These financial results are prepared in accordance with the Indian Accounting Standards ("Ind-AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and are in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
3. As per Ind-AS 108 - Operating Segments, the Company has two reportable Operating Segments namely Pharmaceuticals and Chemicals. The financial information for these segments has been provided in Financial Results as per Ind-AS 108 - Operating Segments.
4. The Board of Directors has declared an Interim Dividend of Rs 4/- (40 %) per Equity Share having face value of Rs 10/- each, for the financial year 2024- 25. The Record Date for the purpose of ascertaining the entitlement of receiving the interim dividend has been fixed on 18th February 2025.
5. The Board of Directors, in their meeting held on 27th December 2024, approved the sub-division / split of each equity share of face value of Rs. 10/- into five Equity Shares of Face Value of Rs. 2/- each, fully paid-up, which was subsequently approved by the shareholders through a Postal Ballot on 31st January 2025. The sub-division / split of shares is in process and will be implemented based on the Record Dated fixed for 11th March 2025.
6. The previous financial period figures have been regrouped/rearranged/restated, wherever considered necessary.

by order of the Board
IOL Chemicals and Pharmaceuticals Limited



Vikas Gupta
Joint Managing Director
DIN: 07198109

Place: Ludhiana
Date: 12th February 2025